FDA approves AbbVie’s Juvmo for Parkinson’s disease treatment

The FDA approved AbbVie's Parkinson's pill, tavapadon, to be sold as Juvmo. The drug is part of its $8.7 billion acquisition of Cerevel Therapeutics. AbbVie expects over $5 billion in combined sales from its Parkinson's portfolio, though analysts caution uptake may be gradual due to Medicare coverage negotiations.

AbbVie's JUVMO (tavapadon) has received FDA approval for Parkinson’s disease, targeting D1/D5 receptors. Phase 3 trials showed improvements in daily living and motor function. The drug can be used alone or with levodopa. AbbVie expects US availability in October 2026, with long-term data needed to assess its advantages over existing treatments.

AbbVie (ABBV) received FDA approval for Juvmo, a new Parkinson's disease treatment, expected to boost its neuroscience portfolio. The company has a 2.54% dividend yield, 85% payout ratio, and 5.2% 3-year dividend growth. Its GF Score is 78, with strong profitability but weak momentum. Insiders sold $17.7M in shares, while institutional activity is mixed.

AbbVie Inc. (NYSE:ABBV) received FDA approval for Juvmo, a Parkinson’s disease drug. The approval was based on Phase 3 trial results showing improved patient functioning. The company plans to launch the drug in the U.S. in October.

AbbVie's Parkinson's drug Juvmo (tavapadon) received FDA approval, sourced from its $8.7B Cerevel acquisition. The drug showed efficacy in Phase 3 trials, addressing motor and daily living complications. AbbVie sees a $5B market opportunity, with Juvmo offering advantages over existing treatments. The company's shares previously dropped 12% after a failed schizophrenia drug study.

AbbVie's Juvmo (tavapadon), a next-gen Parkinson's drug, received FDA approval. It targets D1 receptors, potentially reducing side effects. AbbVie acquired Juvmo via its $8.7bn takeover of Cerevel Therapeutics. Analysts see Juvmo and Vyalev as growth drivers. Parkinson's market expected to reach $7bn by 2033 in 7MM.